Less than a week after Merck &amp; Co. yanked its popular Vioxx arthritis drug off the market, the New England Journal of Medicine voiced strong concerns Wednesday about the safety of Pfizer's bestselling Celebrex.
Seven weeks before Merck &amp; Co. pulled the arthritis drug Vioxx off the market because of safety concerns, federal drug regulators downplayed the significance of scientific findings citing the increased risks, documents released Thursday show.
